Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
30.05. | AstraZeneca receives CHMP recommendation for Imfinzi regimen in bladder cancer | ||
30.05. | Sanofi and Stagecoach Performing Arts partner to highlight impact of autoimmune type 1 diabetes | ||
30.05. | UKDRI researchers to evaluate new blood test for neurodegenerative disease diagnosis | ||
30.05. | In an era of deep uncertainty, life sciences companies require more than agile communications | ||
30.05. | Can we create a world where health is sustainable? | ||
29.05. | Biogen and City Therapeutics to develop RNAi therapies in deal worth over $1bn | ||
29.05. | Sanofi gains access to Alzheimer's candidate through $470m Vigil acquisition | ||
29.05. | The future of customer engagement in biopharma | ||
28.05. | J&J's Darzalex Faspro recommended by FDA panel of experts for smouldering multiple myeloma | ||
28.05. | Merck shares promising phase 3 results for Keytruda in ovarian cancer | ||
28.05. | Improving engagement with clinical trials: time to apply behavioural science | ||
27.05. | Bristol Myers Squibb's perioperative Opdivo regimen granted EC approval in NSCLC | ||
27.05. | Boehringer's nerandomilast shows lung function benefit in phase 3 IPF and PPF trials | ||
27.05. | Exploring AI in pharma: how can we achieve lift-off? | ||
23.05. | BioNTech announces £1bn UK investment to boost regional R&D presence | ||
23.05. | Researchers uncover promising treatment approach for inherited breast cancer | ||
23.05. | Clinical trials - overcoming the barriers to improved enrolment and retention | ||
22.05. | Regeneron to acquire human genetics company 23andMe for $256m | ||
22.05. | AstraZeneca shares late-stage results for Airsupra in mild asthma patients | ||
21.05. | Pfizer gains rights to 3SBio's investigational bispecific antibody in deal worth over $6bn | ||
21.05. | Merck's Welireg granted FDA approval to treat rare tumour types PPGL | ||
21.05. | VML appoints Philippe Huot-Louradour as director of VML Health France | ||
20.05. | J&J's Tremfya approved by MHRA to treat Crohn's disease and ulcerative colitis | ||
20.05. | FDA approves Fujirebio's Lumipulse as first Alzheimer's disease blood test | ||
20.05. | Alnylam shares phase 3 results for Amvuttra in rare heart disease ATTR-CM |